Summary statistics - qualitative results

EQA round: APLA2/26 - Antiphospholipid Antibodies

Deadline: 25.9.2026

Setup: groups - M (measurement principle)

AV = assigned value
CVP = consensus of all participants
CVPG = consensus of the participants' groups
>>> ... expected result
> ... acceptable result
± ... result not assessed

N_{tot} = total number of the results
N_{rel} = relative number of the results

N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	AV		N_{tot}	N_{rel} [%]	Result	Success N_{eva}	N_{suc}	S_{rel} [%]
(465) **anti-β2-glycoprotein 1 screening**			10			0		
Sample A			10			10	10	100
(2) EIA (ELISA)	CVP	>>>	9	90	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP	>>>	1	10	Negative			
Sample B			10			0		
(2) EIA (ELISA)		±	2	20	Negative			
		±	2	20	Inconclusive result (borderline)			
		±	5	50	Positive			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)		±	1	10	Positive			
(467) **anti-β2-glycoprotein 1 IgG**			60			60	59	98
Sample A			60			60	60	100
(2) EIA (ELISA)	CVP	>>>	33	55	Negative			
(3) FIA (FEIA, TRACE)	CVP	>>>	6	10	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP	>>>	21	35	Negative			
Sample B			60			60	59	98
(2) EIA (ELISA)	CVP	>>>	33	55	Negative			
(3) FIA (FEIA, TRACE)	CVP	>>>	6	10	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP	>>>	20	33	Negative			
			1	1,7	Inconclusive result (borderline)			
(468) **anti-β2-glycoprotein 1 IgM**			59			59	57	97
Sample A			59			59	59	100
(2) EIA (ELISA)	CVP	>>>	32	54	Negative			
(3) FIA (FEIA, TRACE)	CVP	>>>	6	10	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP	>>>	21	36	Negative			
Sample B			59			59	57	97
(2) EIA (ELISA)			1	1,7	Negative			
	CVP	>>>	31	53	Positive			
(3) FIA (FEIA, TRACE)	CVP	>>>	6	10	Positive			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)			1	1,7	Negative			
	CVP	>>>	20	34	Positive			
(461) **anti-cardiolipin screening**			12			12	12	100
Sample A			12			12	12	100
(2) EIA (ELISA)	CVP	>>>	11	92	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP	>>>	1	8,3	Negative			
Sample B			12			12	12	100
(2) EIA (ELISA)	CVP	>>>	11	92	Positive			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP	>>>	1	8,3	Positive			
(463) **anti-cardiolipin IgG**			63			63	63	100
Sample A			63			63	63	100
(2) EIA (ELISA)	CVP	>>>	35	56	Negative			
(3) FIA (FEIA, TRACE)	CVP	>>>	6	9,5	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP	>>>	22	35	Negative			
Sample B			63			63	63	100
(2) EIA (ELISA)	CVP	>>>	35	56	Negative			
(3) FIA (FEIA, TRACE)	CVP	>>>	6	9,5	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP	>>>	22	35	Negative			
(464) **anti-cardiolipin IgM**			63			55	52	95
Sample A			63			63	63	100
(2) EIA (ELISA)	CVP	>>>	35	56	Negative			
(3) FIA (FEIA, TRACE)	CVP	>>>	6	9,5	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP	>>>	22	35	Negative			
Sample B			63			55	52	95
(2) EIA (ELISA)			3	4,8	Negative			
	CVP	>>>	30	48	Positive			
(2) EIA (ELISA); (166) Thermo Fisher		±	1	1,6	Inconclusive result (borderline)			
		±	1	1,6	Positive			
(3) FIA (FEIA, TRACE); (166) Thermo Fisher		±	4	6,3	Inconclusive result (borderline)			
		±	2	3,2	Positive			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP	>>>	22	35	Positive			